Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03519971
Other study ID # D933KC00001
Secondary ID 2017-004397-34
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date March 29, 2018
Est. completion date March 31, 2025

Study information

Verified date May 2024
Source AstraZeneca
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center, international study assessing the efficacy and safety of durvalumab given concurrently with platinum-based CRT (durvalumab + standard of care [SoC] CRT) in patients with locally advanced, unresectable NSCLC (Stage III).


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 328
Est. completion date March 31, 2025
Est. primary completion date September 7, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 130 Years
Eligibility Principal inclusion criteria : - Subjects with histologically- or cytologically-documented NSCLC - Locally advanced, unresectable (Stage III) NSCLC - World Health Organisation (WHO) performance status 0-1 - At least one measurable lesion, not previously irradiated - Must have a life expectancy of at least 12 weeks at randomization Principal exclusion criteria : - Receipt of prior or current cancer treatment, including but not limited to, radiation therapy, investigational agents, chemotherapy, Durvalumab and mAbs. - Prior exposure to immune-mediated therapy, including but not limited to, other anti CTLA-4, anti-PD-1, anti-PD-L1, and anti PD L2 antibodies, excluding therapeutic anticancer vaccines. - History of allogeneic organ transplantation - Active or prior documented autoimmune or inflammatory disorders - Uncontrolled intercurrent illness - History of another primary malignancy / leptomeningeal carcinomatosis / active primary immunodeficiency - Active infection including tuberculosis, hepatitis B, hepatitis C, or human immunodeficiency virus - Mixed small cell and NSCLC histology - Any medical contraindication to treatment with platinum-based doublet chemotherapy as listed in the local labelling - Known allergy or hypersensitivity to any of the IPs or any of the IP excipients. - Patients whose radiation treatment plans are likely to encompass a volume of whole lung receiving =20 Gy in total (V20) of more than 35% of lung volume.

Study Design


Intervention

Drug:
Durvalumab
Durvalumab IV (intravenous infusion)
Other:
Placebo
Placebo IV (intravenous infusion)
Drug:
Cisplatin/ Etoposide
Cisplatin/ Etoposide, as per standard of care
Carboplatin/ Paclitaxel
Carboplatin /Paclitaxel, as per standard of care
Pemetrexed/ Cisplatin
Pemetrexed / Cisplatin, as per standard of care
Pemetrexed/ Carboplatin
Pemetrexed / Carboplatin , as per standard of care
Radiation:
Radiation
5 fractions/ week for ~6 weeks (±3 days) (Total 60 Gy)

Locations

Country Name City State
Brazil Research Site Barretos
Brazil Research Site Curitiba
Brazil Research Site Florianópolis
Brazil Research Site Fortaleza
Brazil Research Site Porto Alegre
Brazil Research Site Porto Alegre
Brazil Research Site Porto Alegre
Brazil Research Site Ribeirão Preto
Brazil Research Site Ribeirão Preto
Brazil Research Site São José do Rio Preto
Brazil Research Site Sao Paulo
Czechia Research Site Brno
Czechia Research Site Ostrava
Czechia Research Site Praha 2
Hungary Research Site Budapest
Hungary Research Site Budapest
Hungary Research Site Gyor
Hungary Research Site Gyula
Hungary Research Site Törökbálint
India Research Site Bangalore
India Research Site Chennai
India Research Site Gurgaon
India Research Site Karamsad
India Research Site Mumbai
India Research Site Nasik
India Research Site New Delhi
India Research Site Vadodara
Japan Research Site Bunkyo-ku
Japan Research Site Fukuoka-shi
Japan Research Site Koto-ku
Japan Research Site Kyoto
Japan Research Site Nagoya-shi
Japan Research Site Osakasayama
Japan Research Site Sendai-shi
Japan Research Site Yokohama-shi
Korea, Republic of Research Site Busan
Korea, Republic of Research Site Chungcheongbuk-do
Korea, Republic of Research Site Gyeongsangnam-do
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Korea, Republic of Research Site Seoul
Mexico Research Site Aguascalientes
Mexico Research Site Guadalajara
Mexico Research Site Mérida
Mexico Research Site México
Mexico Research Site Mexico City
Mexico Research Site Orizaba
Peru Research Site La Libertad
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Peru Research Site Lima
Philippines Research Site Cebu City
Philippines Research Site Iloilo
Philippines Research Site Iloilo City
Philippines Research Site Makati
Philippines Research Site Manila
Philippines Research Site Quezon City
Philippines Research Site Taguig City
Poland Research Site Bydgoszcz
Poland Research Site Elblag
Poland Research Site Gdansk
Poland Research Site Olsztyn
Poland Research Site Warszawa
Russian Federation Research Site Arkhangelsk
Russian Federation Research Site Chelyabinsk
Russian Federation Research Site Moscow
Russian Federation Research Site Moscow
Russian Federation Research Site Moscow
Russian Federation Research Site Omsk
Russian Federation Research Site Rostov-on-Don
Russian Federation Research Site Saint-Petersburg
Thailand Research Site Bangkok
Thailand Research Site Bangkok
Thailand Research Site Hat Yai
Thailand Research Site Khon Kaen
Thailand Research Site Mueang
Turkey Research Site Ankara
Turkey Research Site Ankara
Turkey Research Site Antalya
Turkey Research Site Diyarbakir
Turkey Research Site Istanbul
Turkey Research Site Izmir
Vietnam Research Site Hanoi
Vietnam Research Site Hanoi
Vietnam Research Site Ho Chi Minh
Vietnam Research Site Ho Chi Minh city

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Countries where clinical trial is conducted

Brazil,  Czechia,  Hungary,  India,  Japan,  Korea, Republic of,  Mexico,  Peru,  Philippines,  Poland,  Russian Federation,  Thailand,  Turkey,  Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Other Adverse events From the date of randomization until disease progression, assessed up to 4 years.
Primary Progression-free survival (PFS) From date of randomization until the date of objective disease progression or death, assessed up to 4 years.
Secondary Overall Survival (OS) From the date of randomization until death due to any cause, assessed up to 4 years.
Secondary Objective Response Rate (ORR) From the date of Randomisaton until the date of objective disease progression or death, assessed up to 4 years
Secondary Overall Survival at 24 months From the date of randomization until 24 months
Secondary Rate of complete response From the date of Randomisaton until the date of objective disease progression or death, assessed up to 4 years
Secondary Duration of response (DoR) From the date of first documented response (RECIST 1.1.) until the first date of documented progression or death in the absence of disease progression, assessed up to 4 years.
Secondary Disease Control Rate (DCR) From the date of randomization until 24 weeks.
Secondary Time from randomization to second progression PFS2 From the date of randomization to the earliest progression event subsequent to that used for the PFS endpoint or death, up to 4 years
Secondary Time to death or distant metastasis (TTDM) From the date of randomization to until the first date of distant metastasis or death in the absence of distant metastasis, assessed up to 4 years
Secondary Presence of ADA for durvalumab in combination with CRT From the date of randomization until 6 months after date of last IP dose.
Secondary To assess symptoms and health-related QoL in patients treated with durvalumab + SoC CRT compared with placebo + SoC CRT using EORTC QLQ-C30 v3 From the date of randomisation until PFS2.
Secondary To assess symptoms and health-related QoL in patients treated with durvalumab + SoC CRT compared with placebo + SoC CRT using QLQ-LC13 From the date of randomisation until PFS2.
Secondary To assess the PK of durvalumab in blood (peak trough concentration) when in combination with CRT From the date of randomization until 3 months after date of last IP dose.
See also
  Status Clinical Trial Phase
Terminated NCT03087448 - Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Phase 1
Recruiting NCT05042375 - A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Phase 3
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Terminated NCT05414123 - A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
Recruiting NCT05059444 - ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Recruiting NCT05919537 - Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation Phase 1
Recruiting NCT05009836 - Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03219970 - Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
Recruiting NCT05949619 - A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors Phase 1/Phase 2
Recruiting NCT04054531 - Study of KN046 With Chemotherapy in First Line Advanced NSCLC Phase 2
Withdrawn NCT03519958 - Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
Completed NCT03384511 - The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Phase 4
Terminated NCT02580708 - Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer Phase 1/Phase 2
Completed NCT01871805 - A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) Phase 1/Phase 2
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Recruiting NCT05919641 - LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
Completed NCT03656705 - CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma Phase 1